Introduction
============

Breast cancer is the most frequent type of cancer in women (Jemal et al., [@B40]), and the second leading cause of cancer-related death in women worldwide (DeSantis et al., [@B18]). The incidence rates of breast cancer are increasing both in developed and in developing countries (Ferlay et al., [@B25]), whereas the mortality rates have decreased in the last decade \[World Health Organization (WHO), [@B98]; Ferlay et al., [@B25]; DeSantis et al., [@B18]; Jemal et al., [@B40]\], probably because of the investments in early detection and in new pharmacological approaches (Berry et al., [@B6]). Although the recent decrease in the mortality rates proves the efficacy of the current therapeutic protocols, the optimization of available therapies is crucial. Most anticancer drugs are highly toxic, and many patients suffer with adverse reactions that might be persistent throughout the treatment, and sometimes even irreversible. In addition to their obvious impact in patients' quality of life, drug toxicities may also require dose delays, treatment modifications, or even treatment interruption, contributing to the great variability that is usually observed in breast cancer clinical outcomes. This scenario makes breast cancer one of the most appealing targets for evaluation of pharmacogenomic strategies toward personalized medicine.

The current treatment of breast cancer consists of combinations of surgery and adjuvant or neoadjuvant therapeutic approaches, including radiotherapy, cytotoxic chemotherapy, hormonal therapy, and targeted therapy. The treatment choice is routinely based on the estimated risk of recurrence, considering the clinical stage at diagnosis and molecular predictive factors (Soerjomataram et al., [@B86]). Nevertheless, breast cancer is a very heterogeneous disease, with a continuous grading in tumor histology (Hayes et al., [@B31]), different cellular origins (Anderson and Matsuno, [@B4]), and great molecular diversity (Danova et al., [@B15]), which make prognostic estimates a difficult task, especially in early-stage tumors. In an attempt to improve the classical pathology-driven classification of breast tumors, a series of efforts are currently in course, including the description of gene expression patterns (Perou et al., [@B72]; Sørlie et al., [@B87]), and of genomic signatures (Banerji et al., [@B5]; Nik-Zainal et al., [@B63]; Stephens et al., [@B88]). In addition to molecular variations in the tumor, the individual genetic diversity may also contribute for the great heterogeneity in treatment outcomes. Thus, inherited sequence variations (polymorphisms) in genes involved in the pharmacokinetics and pharmacodynamics of anticancer drugs may affect both their efficacy and safety (O'Donnell and Ratain, [@B66]; Ruiz et al., [@B81]).

The chemotherapy of breast cancer includes different options of drug combinations. Anthracycline-based protocols have become the standard adjuvant and neoadjuvant chemotherapy for most patients in view of clinical evidences of improved efficacy in comparison to other previously used protocols (Hassan et al., [@B30]). More recently, taxanes, such as docetaxel or paclitaxel, were added to anthracycline-based protocols, further reducing the risk of recurrence (De Laurentiis et al., [@B17]; Martín et al., [@B56]; Jacquin et al., [@B38]). The most usual protocols for breast cancer chemotherapy nowadays are: docetaxel, doxorubicin, and cyclophosphamide (TAC); docetaxel, epirubicin, and cyclophosphamide (TEC); cyclophosphamide, doxorubicin, and 5-fluorouracil, followed by docetaxel (CAF-T); doxorubicin and cyclophosphamide (AC); and doxorubicin and cyclophosphamide, followed by paclitaxel or docetaxel (AC-P or AC-T). The older protocol cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) is also still used.

Cytotoxic antineoplastic drugs have narrow therapeutic window, and small variations in their plasma concentrations may lead to clinically significant toxicity. Taxanes, for example, may cause severe bone marrow dysfunction, and their toxic effects present great interpatient variability, which appear to be due to interindividual differences in pharmacokinetic parameters (Engels et al., [@B23]). Accordingly, the biotransformation of taxanes is mainly mediated by hepatic CYP450s, which may occur in different isoforms, with distinct functional activities, as a consequence of polymorphisms in their coding genes. Doxorubicin and epirubicin may cause severe cardiotoxicity (Doyle et al., [@B21]; Pinder et al., [@B73]; Gianni et al., [@B27]) and bone marrow dysfunction (Hershman et al., [@B33]; Patt et al., [@B71]). Their biotransformation includes reductions by carbonyl reductases (CBR1 and CBR3) and by aldoketoreductases (AKR1A1 and AKR1C3; Lal et al., [@B48]). Epirubicin also undergoes conjugation by uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7; Innocenti et al., [@B36]). Finally, glutathione (*S*)-transferases (GSTs) may also participate to detoxification. Like the CYP450s, all these xenobiotic metabolizing enzymes are coded by polymorphic genes, which make them potential targets for pharmacogenomic evaluations.

In addition to the cytotoxic antineoplastic drugs, tamoxifen is perhaps the most appealing target for breast cancer pharmacogenomics. It was approved by the FDA in 1977, and since then, it is still the drug with the most striking effect on patients' survival, reducing the annual risk of recurrence by 39% after a 5-year treatment \[Early Breast Cancer Trialists Collaborative Group (EBCTCG), [@B22]\]. The antitumor effects of tamoxifen are mediated by selective modulation of the estrogen receptor, which can be detected in more than two thirds of breast tumors, and to consequent inhibition of estrogen-dependent cell proliferation. However, in spite of the undisputable efficacy and long-term benefits of tamoxifen for breast cancer patients, there is great interindividual variability in the degree of response. Thus, approximately half of the estrogen receptor-positive tumors do not respond to tamoxifen therapy (Jaiyesimi et al., [@B39]; Osborne, [@B69]; Buzdar, [@B11]), and the 15-year recurrence probability in early breast cancer patients treated with tamoxifen for 5 years is approximately one third \[Early Breast Cancer Trialists Collaborative Group (EBCTCG), [@B22]\].

The great interindividual variability observed in the degree of response to tamoxifen can be ascribed to different causes, including failures in patient adherence, drug interactions, and genetic variations affecting tamoxifen pharmacokinetics (Hoskins et al., [@B34]). This variability is of special concern in premenopausal women, who cannot receive aromatase inhibitors, and therefore have less therapeutic options. Thus, it seems crucial to find strategies to ensure tamoxifen response, minimize, or predict individual variability, and improve disease outcomes. Besides the interpatient variability in the degree of response, another motivation for pharmacogenomic studies would be tamoxifen safety. The main concern refers to the risk of endometrial cancer and of thromboembolic events, although these are quite rare events (Fisher et al., [@B26]). The most common side effect of tamoxifen therapy is hot flushes, which are intrinsically correlated with tamoxifen's antiestrogenic activity. Although hot flushes do not represent a life threat, and might become more tolerable with therapy continuation, they can be so intense that patients stop tamoxifen use.

Tamoxifen is considered a prodrug, with very little affinity for the estrogen receptor in its original structure (Coezy et al., [@B13]). The pharmacological actions of tamoxifen are most likely due to its metabolites (Coezy et al., [@B13]; Robertson et al., [@B79]), which are generated in the liver by numerous phase I and II reactions (Mürdter et al., [@B61]). The major metabolite is *N*-desmethyl-tamoxifen, which is generated by CYP3A4/5 and accounts for approximately 90% of tamoxifen metabolites (Desta et al., [@B19]). However, *N*-desmethyl-tamoxifen shows little affinity for the estrogen receptor when compared to two other metabolites, 4-hydroxy-tamoxifen and 4-hydroxy-*N*-desmethyl-tamoxifen (endoxifen; Coezy et al., [@B13]; Jordan, [@B44]; Robertson et al., [@B79]). Because 4-hydroxy-tamoxifen and endoxifen have similar potencies in suppressing estrogen-dependent cell proliferation, but the latter appears to be generated in higher concentrations, endoxifen is believed to be the major active metabolite *in vivo* (Johnson et al., [@B43]; Lim et al., [@B51]). Endoxifen generation is mainly dependent on CYP2D6 activity (Desta et al., [@B19]), and initial observations suggested that genetic polymorphisms in its coding gene, *CYP2D6*, could affect the activity of CYP2D6, resulting in reduced plasma level of endoxifen (Jin et al., [@B42]). Corroborating this notion, *CYP2D6* polymorphisms responsible for reduced CYP2D6 activity were associated with worse breast cancer outcomes in postmenopausal estrogen receptor-positive patients treated with tamoxifen (Goetz et al., [@B28]). These results prompted the FDA to recommend, in 2006, an update in the tamoxifen package insert, alerting for the increased risk of breast cancer recurrence in patients who are CYP2D6 poor metabolizers.

The awareness of the potential impact of *CYP2D6* polymorphisms in tamoxifen pharmacokinetics and pharmacodynamics has motivated a series of pharmacogenomic studies, designed to explore the possibility of using *CYP2D6* genotyping for predicting clinical outcomes in breast cancer patients receiving tamoxifen. According to more recent data, it seems clear that genetic polymorphisms that modulate CYP2D6 activity can indeed modify endoxifen plasma levels (Kiyotani et al., [@B46]; de Graan et al., [@B16]; Irvin et al., [@B37]; Lim et al., [@B50]; Mürdter et al., [@B61]). However, the impact of such pharmacokinetic changes on the individual degree of response to tamoxifen is less clear, and *CYP2D6* genotyping alone has been not enough for predicting breast cancer outcomes in clinical settings (Abraham et al., [@B1]; Rae, [@B74]; Regan et al., [@B77]). It appears, thus, that the pharmacological actions of tamoxifen may be more complex than initially thought, with its antiestrogenic activity being dependent not on a single metabolite, but on a composite action of them (Rae et al., [@B75]). As a consequence of this new assumption, other genetic polymorphisms affecting the pharmacokinetics of tamoxifen might have additional influences on breast cancer outcomes, and should also be considered in pharmacogenomic studies. Likewise, there might be combined influences of genetic polymorphisms on the pharmacokinetics/dynamics of both tamoxifen and other cytotoxic chemotherapeutic drugs, which would require much more complex study designs for evaluation of their impact in clinical settings.

In the present review, we aimed to compile all information available on pharmacogenomic studies involving polymorphisms in xenobiotic metabolizing enzymes and their consequences in clinical outcomes of breast cancer. The analyzed studies explore either tamoxifen or the antineoplastics used in chemotherapy. Instead of focusing on selected positive associations, we performed a systematic review of all published data, evaluating the reported effects on both response and toxicity, as well as all the recorded information of null associations.

Materials and Methods
=====================

A systematic review of the literature data was conducted, which was performed via electronic search of the MEDLINE database (available at PUBMED), and included articles available until August 2012. The search terms were selected using the controlled vocabulary MeSH for the PubMed database. The main search was as follows: \["polymorphism, genetic" (MeSH Terms)\] AND \["breast neoplasms" (MeSH Terms)\] AND \[enzyme (Text Word) OR "enzymes" (MeSH Terms)\] AND \[breast cancer (Title/Abstract)\] AND (xenobiotic OR drug) NOT \["Review" (Publication Type)\]. The following filters were used: Published in the last 10 years; Humans; English; Female.

All abstracts were retrieved, and were used for selection of articles to be used in the review. The pre-defined inclusion criteria were: original articles, including clinical trials, prospective, or retrospective observational studies, describing correlations between polymorphisms in xenobiotic metabolizing enzymes and any clinical response or outcome of breast cancer patients under therapeutic treatment. The exclusion criteria were: letters, commentaries, editorials, or case reports; studies involving only the susceptibility of developing cancer; studies involving only drug transporters or other enzymes not responsible for xenobiotic metabolism; studies involving only pharmacokinetic analyses or correlation with histopathological features, without evaluation of clinical outcomes.

Two reviewers performed the selection of articles to be included in the review according to previously defined inclusion and exclusion criteria, and extracted information for data compilation. A third reviewer examined the lists of selected and excluded articles in order to confirm the eligibility, and checked all the extracted information.

The compiled information was evaluated separately for tamoxifen and for other chemotherapeutic protocols, and focused on the associations between polymorphisms and drug efficacy or drug safety. All the null associations were also collected, compiled, and analyzed.

Results
=======

The literature search resulted in 158 abstracts among the bibliographic references from PUBMED. The abstract reading led to the selection of 30 original articles involving tamoxifen use, and 22 original articles involving any kind of breast cancer chemotherapy. The excluded items (106) consisted of non-original articles (4), articles not involving xenobiotic metabolizing enzymes (85), articles evaluating only the susceptibility to breast cancer (10), articles evaluating only the correlation with histopathological features (3), articles involving only pharmacokinetic analyses (2), 1 article evaluating clinical outcomes not related to breast cancer treatment, and 1 article not involving humans. Among the 49 selected abstracts, 2 articles could not be retrieved, and 7 articles did not fit the inclusion criteria. The excluded articles after full-text reading were: 2 articles not involving xenobiotic metabolizing enzymes, 1 article based on previously published data, 1 article analyzing breast cancer patients together with other cancer patients, 1 article involving only pharmacokinetic analyses, 1 article evaluating clinical outcomes not related to breast cancer treatment, and 1 article which was retracted. The selected articles consisted of 23 original studies involving tamoxifen use, and 20 original studies involving other chemotherapeutic protocols (Figure [1](#F1){ref-type="fig"}).

![**Flow chart of the systematic review of literature data**.](fgene-03-00329-g001){#F1}

The selected studies were mostly based on prospective, observational designs, and focused on the evaluation of different breast cancer outcomes, defined either as primary or secondary endpoints. Some studies also included pharmacokinetic evaluations or other endpoints not directly related to breast cancer treatment. The extracted information was restricted to polymorphisms in xenobiotic metabolizing enzymes and to any clinical outcome directly correlated to breast cancer treatment. The results are distributed in five Tables: Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} present the compiled data involving tamoxifen treatment, and comprise results on both efficacy and safety. Table [1](#T1){ref-type="table"} presents only statistically significant associations, whereas Table [2](#T2){ref-type="table"} presents only null associations. Tables [3](#T3){ref-type="table"}-- [5](#T5){ref-type="table"} present the compiled data involving any adjuvant, neoadjuvant, or palliative chemotherapeutic protocol. Table [3](#T3){ref-type="table"} presents the significant associations involving efficacy outcomes, Table [4](#T4){ref-type="table"} presents any significant association involving toxicities, and Table [5](#T5){ref-type="table"} presents all reported null associations, involving either efficacy or safety outcomes.

###### 

**Effects of polymorphisms in xenobiotic metabolizing enzymes on breast cancer outcomes after tamoxifen treatment**.

  Gene                              SNP            Reference                     Population             Design                 *N*    Reference group^a^                                 Affected group^b^                                                  Outcome             Main results              
  --------------------------------- -------------- ----------------------------- ---------------------- ---------------------- ------ -------------------------------------------------- ------------------------------------------------------------------ ------------------- ------------------------- -------------
  *CYP2D6*                          \*4            Goetz et al. ([@B28])         Adjuvant               Cohort                 223    *\*1/\*1*                                          *\*4/\*4*                                                          RFT                 KM--LR^c^                 0.03
                                                                                                                                      *\*1/\*1*                                          *\*4/\*4*                                                          DFS                 KM--LR^c^                 0.02
                                                   Wegman et al. ([@B96])        Adjuvant               Cohort                 677    *\*4/\*4*                                          *\*1/\*4*                                                          RFS                 KM--LR^c^                 0.04
                                                   Bijl et al. ([@B8])           All incident users     Cohort                 85     *\*1/\*1*                                          *\*4/\*4*                                                          BCSS                HR; 4.1 (1.1--15.9)       0.041
                                                                                                                                      *\*1/\*1*                                          *\*1/\*4* or *\*4/\*4*                                             BCSS                HR; 2.1 (1.1--4.2)        0.031
                                                                                                                                      *\*1*                                              *\*4*                                                              BCSS                HR; 2.0 (1.1--3.4)        0.015
                                    \*6            Abraham et al. ([@B1])        Adjuvant               Case-cohort            3155   *\*1/\*1*                                          *\*1/\*6*                                                          BCSS                HR; 1.95 (1.1--3.4)       0.02
                                    \*10           Lim et al. ([@B49])           Adjuvant, palliative   Cohort                 202    *\*1/\*1*                                          *\*10/\*10*                                                        TTP                 KM--LR^c^                 0.0032
                                                   Xu et al. ([@B99])            Adjuvant               Cohort                 152    *\*1/\*1*                                          *\*10/\*10*                                                        5-Years DFS         HR; 4.7 (1.1--20.0)       0.04
  **COMBINED *CYP2D6* GENOTYPES**                                                                                                                                                                                                                                                                         
                                                   Newman et al. ([@B62])^d^     Adjuvant               Cohort                 115    EM or Het-IM                                       IM                                                                 RFS                 KM--LR^c^                 0.031
                                                                                                                                      *\*1/\*1*                                          PM                                                                 TTR                 HR; 2.9 (0.9--9.4)        0.076
                                                                                                                                      *\*1/\*1*                                          PM                                                                 OS                  HR; 3.5 (0.8--15.4)       0.079
                                                   Schroth et al. ([@B83])^e^    Adjuvant               Retrospective cohort   1325   EM                                                 PM                                                                 TTR                 HR; 1.90 (1.10--3.3)      0.02
                                                   Schroth et al. ([@B84])^f^    Adjuvant               Cohort                 492    EM                                                 PM                                                                 RFS                 HR; 2.77 (1.3--5.9)       0.011^g^
                                                   Kiyotani et al. ([@B46])^h^   Adjuvant               Cohort                 282    EM                                                 Het-EM/IM                                                          TTR                 HR; 1.40 (1.0--1.9)       0.03
                                                                                                                                      *\*1/\*1*                                          *\*1/V*                                                            RFS                 HR; 4.44 (1.3--15.0)      0.000036^g^
                                                                                                                                      *\*1/\*1*                                          *V/V*                                                              RFS                 HR; 9.52 (2.8--32.4)      0.000036^g^
                                                   Teh et al. ([@B90])^i^        Non-palliative         Cohort                 95     EM                                                 IM                                                                 RFS                 OR; 13.14 (1.54--109.9)   0.004
  *CYP2C8*                          \*3            Jernström et al. ([@B41])     Adjuvant               Cohort                 297    *\*1/\*1*                                          *\*1/\*3* or *\*3/\*3*                                             BCSS                HR; 9.10 (1.4--59.6)      0.021
                                                                                                                                      *\*1/\*1*                                          *\*1/\*3* or *\*3/\*3*                                             DFS                 HR; 8.56 (1.5--1.1)       0.015
  *CYP2C8*--*CYP2C9*                *\*3*--*\*2*   Jernström et al. ([@B41])     Adjuvant               Cohort                 297    *\*1/\*1*                                          *\*1/\*3*--*\*1/\*2*                                               DFS                 HR; 2.54 (1.5--5.79)      0.015
  *CYP2C19*                         \*2            Ruiter et al. ([@B80])        All incident users     Cohort                 80     *\*1/\*1*                                          *\*2* Carriers                                                     BCSS                HR; 0.26 (0.08--0.9)      0.03
                                                   van Schaik et al. ([@B94])    Palliative             Cohort                 499    *\*1/\*1*                                          *\*2* Carriers                                                     TTF                 HR; 0.72 (0.57--0.90)     0.04
                                    \*17           van Schaik et al. ([@B94])    Palliative             Cohort                 499    *\*1/\*1*                                          *\*17* Carriers                                                    DFS                 HR; 0.66 (0.46--0.95)     0.025
  *CYP3A5*                          \*3            Wegman et al. ([@B96])        Adjuvant               Cohort                 677    *\*1/\*1* or *\*1/\*3*                             *\*3/\*3*                                                          RFS                 HR; 0.13 (0.02--0.9)      0.03
  *SULT1A1*                         \*2            Nowell et al. ([@B64])        Adjuvant               Cohort                 160    *\*1/\*1* or *\*1/\*2*                             *\*2/\*2*                                                          OS                  HR; 2.9 (1.1--7.6)        
                                                   Wegman et al. ([@B96])        Adjuvant               Cohort                 677    *\*1/\*2* or *\*2/\*2*                             *\*1/\*1*                                                          RFS (2 years TAM)   HR; 0.33 (0.1--0.96)      0.04
  **COMBINED GENOTYPES**                                                                                                                                                                                                                                                                                  
  *SULT1A1* and *UGT2B15*                          Nowell et al. ([@B65])        Adjuvant               Case-cohort            162    *SULT1A1 (\*1/\*1* or *\*1/\*2), UGT2B15\*1/\*1*   *SULT1A1\*2/\*2, UGT2B15 (\*1/\*2* or *\*2/\*2)*                   OS                  HR; 4.40 (1.2--16.5)      0.03^g^
                                                                                                                                      *SULT1A1 (\*1/\*1* or *\*1/\*2), UGT2B15\*1/\*2*   *SULT1A1\*2/\*2, UGT2B15 (\*1/\*2* or *\*2/\*2*                    PFS                 HR; 3.79 (1.2--12.1)      0.03^g^
  *CYP2D6* and *CYP2C19*                           van Schaik et al. ([@B94])    Palliative             Cohort                 499    *CYP2D6\*1/\*1, CYP2C19 \*1/\*1*                   *CYP2D6 (\*1/\*4 or \*4/\*4), CYP2C19 (\*1/\*17* or *\*17/\*17)*   TTF                 KM--LR^c^                 0.031

*BCSS, breast cancer-specific survival; DFS, disease-free survival; TTF, time-to-treatment failure; EM, extensive metabolizer; Het, heterozygous; Homo, homozygous; HR, hazard ratio; IM, intermediate metabolizer; KM--LR, Kaplan--Meier curves and Log-Rank test; OR, odds ratio; OS, overall survival; PFS, progression-free survival; PM, poor metabolizer; RFS, recurrence-free survival; RFT, relapse-free time; RR, risk relative; TAM, tamoxifen; TTP, time to progression; TTR, time to recurrence; V, variant alleles. ^a^The Reference group includes alleles, genotypes, haplotypes, or phenotypes considered as reference for evaluation of outcome parameters. The designation \*1 indicates the reference allele sequence for the analyzed SNP, but may include non-analyzed sequence variations. ^b^The Affected group includes alleles, genotypes, haplotypes, or phenotypes with significantly different outcome parameters, when compared to the Reference group. ^c^The Affected group had a worse outcome. ^d^Newman et al. ([@B62]) -- PM: two copies of the CYP2D6\*3, CYP2D6\*4, or CYP2D6\*5 alleles; a group with concomitant use of a potent CYP2D6 inhibitor in wild-type individuals or moderate inhibitor in heterozygous patients. ^e^Schroth et al. ([@B83]) -- PM: presence of two alleles \*3, \*4, or \*5; EM: absence of alleles \*3, \*4, \*5, \*10, and \*41; Het-EM/IM: presence of two alleles \*10 or \*41, or presence of only one allele \*3, \*4, or \*5; ^f^Schroth et al. ([@B84]) -- EM: presence of alleles \*1, \*2, or \*35; PM: presence of two alleles \*3, \*4, \*5, \*6, \*7, or \*8; ^g^Ptrend values. ^h^Kiyotani et al. ([@B46]) -- V: \*4, \*5, \*10, \*14, \*21, \*36, or \*41; ^i^Teh et al. ([@B90]) -- EM: absence of alleles \*xN, \*4, \*5, \*10, and \*14; Het-IM: \*1/\*10; IM: \*10/\*10 or heterozygous null alleles (\*1/\*4, \*1/\*5, \*1/\*14)*.

###### 

**Null associations between polymorphisms in xenobiotic metabolizing enzymes and breast cancer outcomes after tamoxifen treatment**.

  Gene                          SNP               Reference                    Population           Design        *N*                      Compared groups^a^                 Outcome                                  
  ----------------------------- ----------------- ---------------------------- -------------------- ------------- ------------------------ ---------------------------------- --------- ------------------------------ ------------------------------------
  *CYP2D6*                      *\*4*             Goetz et al. ([@B28])        Adjuvant             Cohort        223                      *\*1/\*1* or *\*1/\*4*             vs.       *\*4/\*4*                      RFS
                                                                                                                                           *\*1/\*1* or *\*1/\*4*             vs.       *\*4/\*4*                      DFS
                                                                                                                                           *\*1/\*1* or *\*1/\*4*             vs.       *\*4/\*4*                      Hot flushes
                                                  Nowell et al. ([@B65])       Adjuvant             Case-cohort   162                      *\*1/\*1*                          vs.       *\*4* Carrier                  PFS
                                                  Wegman et al. ([@B97])       Adjuvant             Cohort        112                      *\*1/\*1*                          vs.       *\*1/\*4* or *\*4/\*4*         RFS
                                                  Wegman et al. ([@B96])       Adjuvant             Cohort        677                      *\*1/\*1*                          vs.       *\*4/\*4*                      RFS
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*4* or *\*4/\*4*         RFS
                                                  Abraham et al. ([@B1])       Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       *\*4* Carrier                  BCSS
                                                  Regan et al. ([@B77])        Adjuvant             Cohort        4393                     *\*1/\*1*                          vs.       *\*4/\*4*                      BCFI
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*4*                      BCFI
                                                  van Schaik et al. ([@B94])   Palliative           Cohort        499                      *\*1/\*1*                          vs.       *\*4* Carrier                  TTF
                                *\*5*             Abraham et al. ([@B1])       Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       *\*5* Carrier                  BCSS
                                *\*9*             Abraham et al. ([@B1])       Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       *\*9* Carrier                  BCSS
                                *\*10*            Okishiro et al. ([@B67])     Adjuvant             Cohort        173                      *\*1/\*1* or *\*1/\*10*            vs.       *\*10/\*10*                    RFS
                                                                                                                                           *\*1/\*1* or *\*1/\*10*            vs.       *\*10/\*10*                    Bone mineral density
                                                                                                                                           *\*1/\*1* or *\*1/\*10*            vs.       *\*10/\*10*                    Total cholesterol
                                                                                                                                           *\*1/\*1* or *\*1/\*10*            vs.       *\*10/\*10*                    Endometrial thickness (1 year TAM)
                                                  Toyama et al. ([@B91])       Adjuvant             Cohort        156                      *\*1/\*1*                          vs.       *\*1/\*10* or *\*10/\*10*      DFS
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*10* or *\*10/\*10*      DFS
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*10* or *\*10/\*10*      BCSS
                                                  Abraham et al. ([@B1])       Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       *\*10* Carrier                 BCSS
                                                  Xu et al. ([@B99])           Adjuvant             Cohort        152                      *\*1/\*1*                          vs.       *\*10* Carrier                 5-Year DSS
                                *\*41*            Abraham et al. ([@B1])       Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       *\*41* Carrier                 BCSS
  Combined *CYP2D6* genotypes                     Abraham et al. ([@B1])^b^    Adjuvant             Case-cohort   3155                     *\*1/\*1*                          vs.       PM or IM                       BCSS
                                                                                                                                           *\*1/\*1*                          vs.       PM                             BCSS
                                                  Regan et al. ([@B77])^d^     Adjuvant             Cohort        4393                     EM                                 vs.       PM                             BCFI
                                                                                                                                           EM                                 vs.       IM                             BCFI
                                                                                                                                           EM                                 vs.       PM or IM                       BCFI
                                                                                                                                           EM                                 vs.       PM                             Hot flushes
                                                                                                                                           EM                                 vs.       IM                             Hot flushes
                                                                                                                                           EM                                 vs.       PM/IM                          Hot flushes
                                                  Teh et al. ([@B90])^c^       Non-palliative       Cohort        95                       EM                                 vs.       Het-IM                         RFS
                                                  Newman et al. ([@B62])^e^    Adjuvant             Cohort        115                      *\*1/\*1*                          vs.       PM                             TTR
                                                                                                                                           *\*1/\*1*                          vs.       PM                             OS
  *CYP2C8*                      \*4               Jernström et al. ([@B41])    Adjuvant             Cohort        297                      *\*1/\*1*                          vs.       *\*1/\*4* or *\*4/\*4*         BCSS
  *CYP2C9*                      \*2               Jernström et al. ([@B41])    Adjuvant             Cohort        297                      *\*1/\*1*                          vs.       *\*1/\*2* or *\*2/\*2*         BCSS
                                \*3                                            *\*1/\*1*            vs.           *\*1/\*3* or *\*3/\*3*   BCSS                                                                        
  *CYP2C19*                     *\*2* and *\*3*   Okishiro et al. ([@B67])     Adjuvant             Cohort        173                      *\*1/\*1, \*1/\*2*, or *\*1/\*3*   vs.       \*2/\*2, \*2/\*3, or \*3/\*3   RFS
                                                                                                                                           *\*1/\*1, \*1/\*2*, or *\*1/\*3*   vs.       \*2/\*2, \*2/\*3, or \*3/\*3   Bone mineral density
                                                                                                                                           *\*1/\*1, \*1/\*2*, or *\*1/\*3*   vs.       \*2/\*2, \*2/\*3, or \*3/\*3   Total cholesterol
                                                                                                                                           *\*1/\*1, \*1/\*2*, or *\*1/\*3*   vs.       \*2/\*2, \*2/\*3, or \*3/\*3   Endometrial thickness (1 year TAM)
                                *\*2*             van Schaik et al. ([@B94])   Palliative           Cohort        499                      *\*1/\*1*                          vs.       \*2 Carrier                    DFS
                                *\*17*            Moyer et al. ([@B60])        All incident users   Cohort        190                      *\*1/\*1*                          vs.       *\*1/\*17* or *\*17/\*17*      DFS
                                                  van Schaik et al. ([@B94])   Palliative           Cohort        499                      *\*1/\*1*                          vs.       *\*17* Carrier                 TTF
  *CYP3A5*                      *\*3*             Goetz et al. ([@B28])        Adjuvant             Cohort        223                      *\*1/\*1* or *\*1/\*3*             vs.       *\*3/\*3*                      RFS
                                                                                                                                           *\*1/\*1* or *\*1/\*3*             vs.       *\*3/\*3*                      DFS
                                                                                                                                           *\*1/\*1* or *\*1/\*3*             vs.       *\*3/\*3*                      Hot flushes
                                                  Tucker et al. ([@B93])       Adjuvant             Cohort        98                       *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Nausea
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Migraines
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Depression
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Vaginal discharge
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Vaginal dryness
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Insomnia
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         Hot flushes
                                *\*6*             Tucker et al. ([@B93])       Adjuvant             Cohort        98                       *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Nausea
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Migraines
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Depression
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Vaginal discharge
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Vaginal dryness
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Insomnia
                                                                                                                                           *\*1/\*1*                          vs.       *\*1/\*6* or *\*6/\*6*         Hot flushes
  *SULT1A1*                     *\*2*             Wegman et al. ([@B97])       Adjuvant             Cohort        112                      *\*1/\*1*                          vs.       *\*1/\*2* or *\*2/\*2*         RFS
                                                  Wegman et al. ([@B96])       Adjuvant             Cohort        677                      *\*1/\*1*                          vs.       *\*1/\*2* or *\*2/\*2*         RFS
                                Copy number       Moyer et al. ([@B60])        All incident users   Cohort        190                      ≤*2*                               vs.       \>*2*                          DFS
  *UGT1A8*                      *\*3*             Ahern et al. ([@B3])         Non-palliative       Case-cohort   541                      *\*1/\*1*                          vs.       *\*1/\*3* or *\*3/\*3*         RFS
  *UGT2B7*                      *\*2*             Ahern et al. ([@B3])         Non-palliative       Case-cohort   541                      *\*1/\*1*                          vs.       *\*2/\*2*                      RFS
  *UGT2B15*                     *\*2*             Nowell et al. ([@B65])       Adjuvant             Case-cohort   162                      *\*1/\*1*                          vs.       *\*1/\*2*                      RFS
                                                                                                                                           *\*1/\*1*                          vs.       *\*2/\*2*                      
                                                  Wegman et al. ([@B96])       Adjuvant             Cohort        677                      *\*1/\*1*                          vs.       *\*1/\*2, \*2/\*2*             RFS
                                                  Ahern et al. ([@B3])         Non-palliative       Case-cohort   541                      *\*1/\*1*                          vs.       *\*2/\*2*                      RFS

*Abbreviations: BCFI, breast cancer-free interval; BCSS, breast cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival; EM, extensive metabolizer; Het, heterozygous; Homo, homozygous; IM, intermediate metabolizer; PFS, progression-free survival; PM, poor metabolizer; RFS, recurrence-free survival; TTF, time-to-treatment failure; V, variant alleles. ^a^The designation \*1 indicates the reference allele sequence for the analyzed SNP, but may include non-analyzed sequence variations. ^b^Abraham et al. ([@B1]) -- PM: presence of at least one allele \*4, \*5, or \*6; IM: presence of one or two alleles \*9, \*10, or \*41; ^c^Teh et al. ([@B90]) -- EM: absence of alleles \*xN, \*4, \*5, \*10, and \*14; Het-IM: \*1/\*10; IM: \*10/\*10 or heterozygous null alleles (\*1/\*4, \*1/\*5, \*1/\*14); ^d^Regan et al. ([@B77]) -- PM: presence of alleles \*3, \*4, \*6, or \*7; IM: \*41/\*41 or \*41/PM; ^e^Newman et al. ([@B62]) -- PM: two copies of the CYP2D6\*3, CYP2D6\*4, or CYP2D6\*5 alleles; a group with concomitant use of a potent CYP2D6 inhibitor in wild-type individuals or moderate inhibitor in heterozygous patients*.

###### 

**Effects of polymorphisms in xenobiotic metabolizing enzymes on breast cancer outcomes after chemotherapy**.

  Gene                     SNP                        Reference                 Population/design                   Protocol               *N*   Reference group^a^              Affected group^b^                  Outcome                 Main results           
  ------------------------ -------------------------- ------------------------- ----------------------------------- ---------------------- ----- ------------------------------- ---------------------------------- ----------------------- ---------------------- -------
  *CYP1A1*                 *m2*                       Chacko et al. ([@B12])    Adjuvant, neoadjuvant, metastatic   Not informed           79    *wt/wt*                         *wt/m2* or *m2/m2*                 BCSS                    HR; 18.3 (2.4--140)    0.005
  *CYP1B1*                 *\*3*                      Marsh et al. ([@B55])     Stages IIIA -- IV                   Paclitaxel-based       84    *\*1/\*1 or \*1/\*3*            \*3/\*3                            PFS                     KM--LR^c^              0.037
  *CYP2B6*                 *\*2*                      Bray et al. ([@B9])       Adjuvant                            AC                     230   *\*1/\*1*                       *\*1/\*2*                          TTP                     KM--LR^c^              0.002
                           *\*4*                      Bray et al. ([@B9])       Adjuvant                            AC                     230   *\*1/\*1*                       *\*4/\*4*                          OS                      KM--LR^c^              0.05
                           *\*9*                      Bray et al. ([@B9])       Adjuvant                            AC                     230   *\*1/\*1*                       *\*9/\*9*                          OS                      KM--LR^c^              0.003
  *CYP3A4*                 *\*1B*                     Gor et al. ([@B29])       Adjuvant                            CAF (+ CTX/thiotepa)   350   *\*1B/\*1A*                     *\*1A/\*1A*                        DFS                     HR; 2.79 (1.5--5.1)    0.001
  *GSTA1*                  *\*B*                      Sweeney et al. ([@B89])   Neoadjuvant                         CTX-based                    *\*A/\*A or \*A/\*B*            *\*B/\*B*                          OS                      HR; 0.5 (0.3--0.8)     0.01
  *GSTP1*                  *313A* \> *G*              Huang et al. ([@B35])     Adjuvant                            FEC                    192   *A/A (Ile/Ile)*                 *A/G (Ile/Val) or G/G (Val/Val)*   Early relapse^d^        χ^2^ Test^c,e^         0.014
                           *313A* \> *G*              Zhang et al. ([@B102])    Neoadjuvant                         EPI and CTX            120   *G/G (Val/Val)*                 *A/A (Ile/Ile) or A/G (Ile/Val)*   Pathological response   OR; 0.4 (0.2--0.96)    0.024
  *GSTT1*                  Deletion (null)            Chacko et al. ([@B12])    Adjuvant, neoadjuvant, metastatic   Not informed           79    Non-null                        Null                               BCSS                    HR; 0.2 (0.0--0.9)     0.039
  *UGT2B7*                 *His268Tyr*                Parmar et al. ([@B70])    Adjuvant                            EPI                    205   Two *268Tyr* alleles            At least one *268His* allele       DFS                     HR; 2.64 (1.2--5.7)    0.014
  **COMBINED GENOTYPES**                                                                                                                                                                                                                                           
  *GSTP1/SOD2*             *313A* \> *G*              Bewick et al. ([@B7])     Metastatic/retrospective cohort     MITOX and CTX          95    *GSTP1 AA, and SOD2 CC or CT*   *GSTP1 GG or AG, and SOD2 TT*      BCSS                    HR; 2.17 (1.1--4.2)    0.013
                           *313A* \> *G/16C* \> *T*   Bewick et al. ([@B7])     Metastatic/retrospective cohort     MITOX and CTX          96    *GSTP1 AA, and SOD2 CC or CT*   *GSTP1 GG or AG, and SOD2 TT*      PFS                     HR; 2.89 (1.4--5. 9)   0.002

*Abbreviations: AC, adriamycin and cyclophosphamide; BCSS, breast cancer-specific survival; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil; CTX, cyclophosphamide; DFS, disease-free survival; EPI, epirubicine; FEC, 5-fluorouracil, epirubicine, and cyclophosphamide; HR, hazard ratio; KM--LR, Kaplan--Meier curves and Log-Rank test; MITOX, mitoxantrone; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RR, relative risk; TEC, docetaxel, epirubicine, and cyclophosphamide; TTP, time to progression. WT, wild-type allele. ^a^The *Reference group* includes alleles, genotypes, haplotypes, or phenotypes considered as reference for evaluation of outcome parameters. The designation \*1 indicates the reference allele sequence for the analyzed SNP, but may include non-analyzed sequence variations. ^b^The *Affected group* includes alleles, genotypes, haplotypes, or phenotypes with significantly different outcome parameters, when compared to the *Reference group*. ^c^The *Affected group* had a worse outcome. ^d^Early relapse was designated as the development of new recurrent or distant metastatic lesions within 2 years after receiving postoperative chemotherapy; ^e^χ^2^ test*.

###### 

**Effects of polymorphisms in xenobiotic metabolizing enzymes on the toxicity to chemotherapy for breast cancer**.

  Gene       SNP           Reference                 Population                             *N*   Protocol                    Outcome                                  Reference group                      Affected group                       Main results             
  ---------- ------------- ------------------------- -------------------------------------- ----- --------------------------- ---------------------------------------- ------------------------------------ ------------------------------------ ------------------------ -------------
  *CBR3*     *G11A*        Fan et al. ([@B24])       Neoadjuvant                            99    Doxorubicin and docetaxel   Leucopenia at nadir^a^                   *GG*                                 *GA, AA*                             Trend test               0.019
                                                                                                                              Thrombocytopenia at nadir^a^             *GG*                                 *GA, AA*                             Trend test               0.026
  *CYP1B1*   *\*3*         Rizzo et al. ([@B78])     Adjuvant, neoadjuvant, or metastatic   95    Taxanes                     Hypersensitivity^b^                      *CG* or *GG*                         *CC*                                 OR; 0.136 (0.05--0.37)   0.014
  *CYP2B6*   *\*2*         Bray et al. ([@B9])       Adjuvant                               230   AC                          Toxicity and dose delay                  *CT* or *TT*                         *CC*                                 χ2 Test^c^               0.013
  *CYP3A5*   *\*3*         Tsai et al. ([@B92])      Adjuvant or neoadjuvant                59    TEC                         Febrile neutropenia                      \*3/\*3                              \*1/\*3                              RR; 7.17 (1.10--3.55)    *p* \< 0.05
                           Tsai et al. ([@B92])      Adjuvant or neoadjuvant                59    TEC                         Fever                                    \*3/\*3                              \*1/\*3                              RR; 3.29 (1.03--10.05)   *p* \< 0.05
                           Tsai et al. ([@B92])      Adjuvant or neoadjuvant                59    TEC                         Neutropenia                              \*3/\*3                              \*1/\*3                              RR; 3.29 (1.03--10.5)    *p* \< 0.05
  *GSTP1*    *Ile105Val*   Zárate et al. ([@B101])   Adjuvant                               95    Anthracycline-based         Hematological toxicity (grades 3 or 4)   *A/A (Ile/Ile)* or *A/G (Ile/Val)*   *G/G (Val/Val)*                      HR; 6.4 (1.05--39)       0.044
                           Yao et al. ([@B100])      Adjuvant                               874   CAF or CMF                  Neutropenia (grades 3 or 4)              *A/A (Ile/Ile)*                      *A/G (Ile/Val)* or *G/G (Val/Val)*   OR; 0.63 (0.41--0.97)    0.04
                           Yao et al. ([@B100])      Adjuvant                               874   CAF or CMF                  Leucopenia                               *A/A (Ile/Ile)*                      *A/G (Ile/Val)* or *G/G (Val/Val)*   OR; 0.59 (0.39--0.89)    0.01
                           Zhang et al. ([@B102])    Neoadjuvant                            120   EPI and CTX                 Severe toxicity (grades 3 or 4)          *G/G (Val/Val)*                      *A/A (Ile/Ile) or A/G (Ile/Val)*     OR; 0.35 (0.13--0.78)    0.006

*Abbreviations: AC, driamycin and cyclophosphamide; BCSS, breast cancer-specific survival; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil; CMF, cyclophosphamide, metothrexate, and 5-fluorouracil; CTX, cyclophosphamide; DFS, disease-free survival; EPI, epirubicine; FEC, 5-fluorouracil, epirubicine, and cyclophosphamide; HR, hazard ratio; IM, intermediate metabolizer; KM--LR. Kaplan--Meier curves and Log-Rank test; MITOX, mitoxantrone; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RR, relative risk; TEC, docetaxel, epirubicine, and cyclophosphamide; TTP, time to progression. ^a^Nadir was defined as the lowest count documented within 21 days of doxorubicin administration; ^b^The hypersensitivity reactions were characterized by acute dyspnea, flushing of the face, chest constraint, hypotension, and rash; ^c^χ^2^ test*.

###### 

**Null associations between polymorphisms in xenobiotic metabolizing enzymes and breast cancer outcomes after chemotherapy**.

  Gene        SNP                                    Reference                  Population                          Protocol                    *N*   Outcome                                                          Compared groups
  ----------- -------------------------------------- -------------------------- ----------------------------------- --------------------------- ----- ---------------------------------------------------------------- -----------------------------------------
  *CBR3*      *730G* \> *A*                          Fan et al. ([@B24])        Neoadjuvant                         Doxorubicin and docetaxel   99    Hematological toxicity or tumor reduction^a^                     *GG, GA*, and AA
  *CYP2B6*    *\*3, \*5, \*8*                        Bray et al. ([@B9])        Adjuvant                            AC                          230   DFS and toxicity                                                 \*1/\*1 vs. any variant
              *\*2, \*3, \*4, \*5, \*8*, and *\*9*   Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              \*1/\*1 vs. any variant
              *\*9*                                  Yao et al. ([@B100])       Adjuvant                            CAF or CMF                  449   Hematological toxicity                                           *GG* vs. *GT* or *TT*
  *CYP2C8*    *\*1, \*2, \*3*, and *\*4*             Rizzo et al. ([@B78])      Adjuvant, neoadjuvant, metastatic   Taxanes                     95    Hematological toxicity, neurotoxicity, and hypersensitivity^b^   \*1/\*1 vs. any variant
  *CYP2C9*    *\*2* and *\*3*                        Bray et al. ([@B9])        Adjuvant                            AC                          230   BCSS and toxicity                                                \*1/\*1 vs. any variant
                                                     Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              \*1/\*1 vs. any variant
  *CYP2C19*   *\*2*                                  Bray et al. ([@B9])        Adjuvant                            AC                          230   BCSS and toxicity                                                \*1/\*1 vs. any variant
  *CYP2D6*    *\*10*                                 Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              *G/G* vs. *G/A* vs. *A/A*
  *CYP3A4*    *\*4*                                  Tsai et al. ([@B92])       Adjuvant or neoadjuvant             TEC                         59    Toxicity                                                         *\*1/\*1* vs. *\*1/\*4*
              *\*5*                                  Tsai et al. ([@B92])       Adjuvant or neoadjuvant             TEC                         59    Toxicity                                                         *\*1/\*1* vs. *\*1/\*5*
              *\*18*                                 Tsai et al. ([@B92])       Adjuvant or neoadjuvant             TEC                         59    Toxicity                                                         *\*1/\*1* vs. *\*1/\*18*
              *\*1B*                                 Yao et al. ([@B100])       Adjuvant                            CAF or CMF                  456   Hematological toxicity                                           *\*1/\*1* vs. *\*1/\*1B* or *\*1B/\*1B*
              *\*1G*                                 Zhang et al. ([@B102])     Neoadjuvant                         EPI and CTX                 120   Pathological response and toxicity                               *CC* vs. *CT* vs. *TT*
  *CYP3A5*    *\*3*                                  Bray et al. ([@B9])        Adjuvant                            AC                          230   BCSS and toxicity                                                \*1/\*1 vs. any variant
                                                     Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              *\*1/\*3, \*1/\*1, \*3/\*3*
                                                     Zhang et al. ([@B102])     Neoadjuvant                         EPI and CTX                 120   Pathological response and toxicity                               
              *\*6*                                  Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              *\*1/\*1* vs. *\*1/\*6*
  *CYP3A7*    *\*2*                                  Zhang et al. ([@B102])     Neoadjuvant                         EPI and CTX                 120   Pathological response and toxicity                               *AA, AT, TT*
  *GSTA1*     rs3957356-69A \> G                     Yao et al. ([@B100])       Adjuvant                            CAF or CMF                  414   Hematological toxicity                                           *GG* vs. *GA* or *AA*
  *GSTM1*     *Null*                                 Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              Null vs. non-null
                                                     Oliveira et al. ([@B68])   Neoadjuvant                         FEC                         40    Pathological response                                            Null vs. non-null
                                                     Mishra et al. ([@B57])     Neoadjuvant                         CAF -- docetaxel            45    Pathological response                                            Null vs. non-null
                                                     Saadat et al. ([@B82])     Neoadjuvant                         CAF or TAC                  101   Pathological response                                            Null vs. non-null
  *GSTO2*     rs156697 (Asn142Asp)                   Saadat et al. ([@B82])     Neoadjuvant                         CAF or TAC                  101   Pathological response                                            *Asn/Asn, Asn/Asp, Asp/Asp*
  *GSTP1*     *Ala114Val*                            Bewick et al. ([@B7])      Metastatic                          MITOX and CTX               95    PFS and BCSS                                                     *AA, AG, GG*
              *Ile105Val*                            Bewick et al. ([@B7])      Metastatic                          MITOX and CTX               95    PFS and BCSS                                                     *CC, CT, TT or GG, GA, AA*
                                                     Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              *GG, GA, AA*
                                                     Oliveira et al. ([@B68])   Neoadjuvant                         FEC                         40    Pathological response                                            *Ile/Val* vs. *Ile/Ile*
                                                     Yao et al. ([@B100])       Adjuvant                            CAF or CMF                  874   DFS                                                              *GG, GA, AA*
  *GSTT1*     *Null*                                 Gor et al. ([@B29])        Adjuvant                            CAF (+ CTX/thiotepa)        350   DFS                                                              Null vs. non-null
                                                     Oliveira et al. ([@B68])   Neoadjuvant                         FEC                         40    Pathological response                                            Null vs. non-null
                                                     Mishra et al. ([@B57])     Neoadjuvant                         CAF -- docetaxel            45    Pathological response                                            Null vs. non-null
                                                     Saadat et al. ([@B82])     Neoadjuvant                         CAF or TAC                  101   Pathological response                                            Null vs. non-null
  *GSTZ1*     rs7975 *(Glu32Lys)*                    Saadat et al. ([@B82])     Neoadjuvant                         CAF or TAC                  101   Pathological response                                            *Glu/Glu, Glu/Lys, Lys/Lys*

*Abbreviations: AC, adriamycin and cyclophosphamide; BCSS, breast cancer-specific survival; CAF, cyclophosphamide, adriamycin, and 5-fluorouracil; CMF, cyclophosphamide, metothrexate, and 5-fluorouracil; CTX, cyclophosphamide; DFS, disease-free survival; EPI, epirubicine; FEC, 5-fluorouracil, epirubicine, and cyclophosphamide; MITOX, mitoxantrone; OR, odds ratio; OS, overall survival; PFS, progression-free survival; TEC, docetaxel, epirubicine, and cyclophosphamide. ^a^Tumor reduction was defined as ≥25% tumor reduction after the first cycle of doxorubicin; ^b^The hypersensitivity reactions were characterized by acute dyspnea, flushing of the face, chest constraint, hypotension, and rash*.

Among the 20 studies involving tamoxifen use, 16 explored the effects of *CYP2D6* polymorphisms, either considering polymorphisms individually or in their combined genotypes and expected phenotypes. The other four articles evaluated polymorphisms in other genes different from *CYP2D6*. Thus, Nowell et al. ([@B64]) examined the relationship between the *SULT1A1\*2* allele and survival in a cohort of 337 women (160 receiving tamoxifen); Tucker et al. ([@B93]) evaluated the impact of *CYP3A5* polymorphisms on tamoxifen side effects in 98 postmenopausal women; Jernström et al. ([@B41]) investigated the frequency of *CYP2C8* and *CYP2C9* polymorphisms in relation to disease-free survival in a prospective series of 652 breast cancer patients (297 receiving tamoxifen), and Ruiter et al. ([@B80]) evaluated the impact of *CYP2C19\*2* and *CYP2C19\*3* on breast cancer mortality rate in 215 breast cancer patients (80 using tamoxifen). Among the 16 studies evaluating *CYP2D6* polymorphisms, 7 studies also analyzed other genes: Nowell et al. ([@B65]) analyzed *UGT2B15* polymorphisms; Wegman et al. ([@B97]) examined variants of *SULT1A1*; Wegman et al. ([@B96]) evaluated *CYP3A5, SULT1A1*, and *UGT2B15*; Okishiro et al. ([@B67]) analyzed *CYP2C19*; Kiyotani et al. ([@B46]) did not evaluate polymorphisms involving xenobiotic metabolizing enzymes, but examined gene polymorphisms affecting drug transporters (ABCB1, ABCC2, ABCG2); and Moyer et al. ([@B60]) examined *SULT1A1* and *CYP2C19* polymorphisms.

The compiled results in Table [1](#T1){ref-type="table"} indicate that some functional polymorphisms affecting the enzymatic activities of CYP2D6, CYP3A5, CYP2C8, CYP2C19, SULT1A1, or UGT2B15 could significantly affect breast cancer outcomes. Thus, *CYP3A5\*3* and *CYP2C19\*2* seem to be beneficial with regards to the risk of recurrence or to breast cancer-specific survival, respectively. All the other polymorphisms with reported significant effects on breast cancer clinical outcomes, i.e., *CYP2C8\*3, CYP2D6\*4, CYP2D6\*6, CYP2D6\*10, SULT1A1\*2*, and *UGT2B15\*2*, were associated with an apparent worse response to tamoxifen, resulting in higher risk of tumor recurrence, shorter breast cancer-specific survival, or shorter overall survival.

With regards to *CYP2D6\*4*, the work by Wegman et al. ([@B96]) represents an exception, since it shows an apparent beneficial effect of the genotype *CYP2D6\*1/\*4* in relation to recurrence-free survival. This apparently protective effect, however, was not seen for patients homozygous for the allele *\*4*, who were similar to patients with the wild-type genotype in relation to recurrence-free survival. Although there are no other reports suggesting any beneficial effect of *CYP2D6* polymorphisms in relation to breast cancer outcomes, there is much inconsistency in the supposed detrimental effects of the variant alleles with regards to the risk of recurrence. Thus, only Bijl et al. ([@B8]), with a very limited number of patients, reported an apparent trend between heterozygous and homozygous variants of the allele \*4. Goetz et al. ([@B28]) only found significant effects when comparing the homozygous variant genotype *\*4/\*4* to the homozygous wild-type genotype *\*1/\*1*. All the other published studies involving *CYP2D6\*4* indicate no significant effect for the variant allele, either in heterozygosis or in homozygosis (Table [2](#T2){ref-type="table"}). The lack of significant independent effect of the allele \*4 cannot be attributed to low statistical power, since it was confirmed by the two largest studies (Abraham et al., [@B1]; Regan et al., [@B77]). The study by Abraham et al. ([@B1]) also show no significant effects on breast cancer outcomes regarding the *CYP2D6* variant alleles \*5, \*9, \*10, and \*41. The lack of significant effects with the variant genotypes of *CYP2D6\*10* had already been reported by Okishiro et al. ([@B67]) and Toyama et al. ([@B91]).

Other studies analyzed multiple *CYP2D6* polymorphisms (alleles *\*3, \*4, \*5, \*6, \*7, \*10, \*14, \*21, \*36--\*36, \*41*) in different combinations, and, based on their expected functional impact on the activity of CYP2D6 enzyme, characterized individual metabolizing phenotypes (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Although some studies have suggested that reduced CYP2D6 enzymatic activity might contribute for higher risk of breast cancer recurrence (Table [1](#T1){ref-type="table"}), the recent results of the large studies by Abraham et al. ([@B1]) and Regan et al. ([@B77]) indicate no significant differences in relation to breast cancer-specific survival, either for poor or intermediate CYP2D6 metabolizers, which were characterized based on alleles *\*3, \*4, \*5, \*6, \*7, \*10*, and *\*41* (Table [2](#T2){ref-type="table"}).

With regards to other polymorphisms that could affect tamoxifen metabolism, there are fewer studies available, and none of them are based on multicenter large populations. In addition, the published data are more diverse in relation to the polymorphisms and to the outcomes that were analyzed, with some polymorphisms being evaluated in only one study. Therefore, the available information does not support combined analyses, and any general conclusion is only tentative.

The only study involving *CYP2C8* (alleles *\*3* and *\*4*) or *CYP2C9* (alleles *\*2* and *\*3*) was the work by Jernström et al. ([@B41]), who described an increased risk of early breast cancer-related deaths associated with the haplotype *CYP2C8\*1/\*3/CYP2C9\*1/\*2* (Table [1](#T1){ref-type="table"}). According to the authors, the effect appears to be driven by *CYP2C8\*3*, which presents strong, but not complete linkage disequilibrium with *CYP2C9\*2*. The authors found no significant effects associated with *CYP2C8\*4, CYP2C9\*2*, or *CYP2C9\*3*, when evaluated independently (Table [2](#T2){ref-type="table"}). With regards to *CYP2C19*, Okishiro et al. ([@B67]) analyzed the alleles *\*2* and *\*3*, Ruiter et al. ([@B80]) analyzed only the allele *\*2*, and Moyer et al. ([@B60]) analyzed the allele *\*17*. Ruiter et al. ([@B80]) were the only ones to describe an apparent protective effect for the allele *\*2*, with longer breast cancer-specific survival among patients carrying any variant genotype (Table [1](#T1){ref-type="table"}). *CYP3A5* was analyzed by Goetz et al. ([@B28]), Tucker et al. ([@B93]), and Wegman et al. ([@B96]). Tucker et al. ([@B93]) evaluated *CYP3A5\*3* and *CYP3A5\*6*, whereas the other two studies analyzed only *CYP3A5\*3*. Wegman et al. ([@B96]) reported a significantly improved recurrence-free survival among *CYP3A5\*3*-homozygous patients (Table [1](#T1){ref-type="table"}), which was not seen by Goetz et al., [@B28]; Table [2](#T2){ref-type="table"}). Tucker et al. ([@B93]) did not evaluate response outcomes, and reported no significant association between *CYP3A5* polymorphisms and adverse events during tamoxifen treatment (Table [2](#T2){ref-type="table"}). *SULT1A1* was studied by Nowell et al. ([@B64]), Wegman et al. ([@B97]), Wegman et al. ([@B96]), and Moyer et al. ([@B60]). The first three studies evaluated the polymorphism *SULT1A1\*2*, whereas Moyer et al. ([@B60]) analyzed the number of gene copies in breast tumors. The study by Nowell et al. ([@B64]) was the only one to report a significant effect of the homozygous *\*2*/*\*2* on patients' overall survival (Table [1](#T1){ref-type="table"}). Wegman et al. ([@B96]) also reported significant detrimental effects of the variant allele *\*2* on recurrence-free survival after 2 years of tamoxifen treatment (Table [1](#T1){ref-type="table"}), but this association was no longer existent after 5 years of tamoxifen treatment (Table [2](#T2){ref-type="table"}). The polymorphisms *UGT1A8\*3, UGT2B7\*2*, and *UGT2B15\*2* were analyzed by Ahern et al. ([@B3]), who found no significant associations between their variant alleles and recurrence-free survival in breast cancer patients under adjuvant or neoadjuvant treatment with tamoxifen (Table [2](#T2){ref-type="table"}). *UGT2B15\*2* was also analyzed by Nowell et al. ([@B64]) and Wegman et al. ([@B96]). Nowell et al. ([@B64]) were the only ones to report a significant higher risk of disease progression for patients carrying the variant allele \*2 (either in heterozygosis or in homozygosis) in combination with the genotype *SULT1A1\*2/\*2* (Table [1](#T1){ref-type="table"}). In conclusion, there is no consistency among the few and sparse results regarding polymorphisms in xenobiotic metabolizing enzymes different from CYP2D6 and their impact on tamoxifen efficacy or safety. Taken together, these results do not suggest clinically relevant implications of such pharmacogenetic targets for tamoxifen treatment.

The published data regarding functional polymorphisms in xenobiotic metabolizing enzymes and breast cancer chemotherapy present even greater diversity in design than observed for studies involving tamoxifen. As expected, these studies involve different patients' subgroups, and comprise distinct chemotherapeutic protocols. The study designs are also very diverse in the selection of polymorphisms and in analyzed outcomes, with some studies evaluating response outcomes, whereas others focus only in adverse effects. Table [3](#T3){ref-type="table"} summarizes all the available data for significant associations with response outcomes. The compiled information indicates worse outcomes (higher recurrence risk or shorter breast cancer-specific survival) for the polymorphisms *CYP1A1m2, CYP1B1\*3, CYP2B6\*2, \*4*, and *\*9, CYP3A4\*1B, GSTP1A313G*, and *UGT2B7His268Tyr*, whereas a beneficial effect is observed for the variant genotype *GSTA1\*B/\*B* (better overall survival) and for the *GSTT1*Null genotype (longer breast cancer-specific survival). Bewick et al. ([@B7]) found no significant effect for *GSTP1A313G* when evaluated independently, but reported a combined effect of *GSTP1A313G* variant genotypes and *SOD2C16CT* variant homozygous genotype resulting in shorter progression-free survival and breast cancer-specific survival for patients using mitoxantrone and cyclophosphamide.

Table [4](#T4){ref-type="table"} summarizes all the available data for significant associations with chemotherapy-related toxicity outcomes. The compiled results indicate higher risk of severe hematological reactions (neutropenia, leucopenia, or thrombocytopenia) for patients with *CBR3 G11A* or *GSTP1A313G* variant genotypes. The other analyzed polymorphisms (*CYP1B1\*3, CYP2B6\*2, CYP3A5\*3)* showed beneficial effects in relation to the risk of hematological toxicities for patients using anthracycline-based protocols and/or taxanes.

Finally, Table [5](#T5){ref-type="table"} summarizes all the null associations involving polymorphisms in xenobiotic metabolizing enzymes and breast cancer outcomes after chemotherapy. The compiled data comprise various studies evaluating many polymorphisms, but, in most cases, there is only one study for each polymorphism. Because most studies are based on a relatively small number of patients using specific protocols, the compiled information is very diffuse and does not allow definite conclusions or general assumptions. Therefore, the results must be analyzed independently, considering the particularities of each study.

The only polymorphisms that were analyzed by at least two independent studies with similar designs were *CYP2B6\*2, \*3, \*5, \*8*, and *\*9, CYP2C9 \*2* and *\*3*, and *CYP3A5\*3*, which were studied by Bray et al. ([@B9]) and Gor et al. ([@B29]), evaluating survival in patients under adjuvant chemotherapy with anthracycline-based protocols. *GSTM1null* was also studied under similar conditions by Oliveira et al. ([@B68]), Mishra et al. ([@B57]), and Saadat et al. ([@B82]), who evaluated the pathological response to neoadjuvant chemotherapy with anthracyclines and taxanes. In the case of *CYP2B6\*2*, Bray et al. ([@B9]) reported a significant association between the heterozygous variant genotype and shorter time to progression for patients under adjuvant chemotherapy with the protocol AC (Table [3](#T3){ref-type="table"}), whereas Gor et al. ([@B29]) found no significant effect on disease-free survival for patients under adjuvant chemotherapy with the protocol CAF (+ CTX/Thiotepa; Table [5](#T5){ref-type="table"}). In the case of *CYP3A5\*3*, Tsai et al. ([@B92]) found that patients carrying the heterozygous *\*1/\*3* genotype demonstrated more side effects of fever, pleural effusion, and febrile neutropenia than those with the homozygous *\*3/\*3* genotype (Table [4](#T4){ref-type="table"}). Bray et al. ([@B9]), evaluating dose delays in adjuvant chemotherapy with AC, found no significant associations with *CYP3A5\**3 variant alleles (Table [5](#T5){ref-type="table"}), which the authors interpreted as no significant differences in clinically relevant toxicities. Zhang et al. ([@B102]), evaluating severe toxicities (grade 3 or 4) to neoadjuvant chemotherapy with EPI and CTX, also found no significant associations with *CYP3A5\**3 variant alleles (Table [5](#T5){ref-type="table"}). It is not clear whether the discrepancies in the association results reported by different studies involving the same polymorphisms can be attributed to distinct chemotherapeutic protocols, or to other uncontrolled causes of variability.

Discussion
==========

The field of pharmacogenetics (or pharmacogenomics) has developed with the goal of identifying genetic causes of interindividual differences in pharmacological response, and of using such genetic information to predict one individual's profile of drug safety and efficacy. In this regard, pharmacogenetic studies are designed to evaluate the correlation between genotypes and phenotypes, and, therefore, provide scientific evidence for the implementation of individualized drug prescriptions, as part of a conduct of personalized medicine. Nevertheless, the characterization of phenotypes may not be easy to accomplish, especially in clinical settings, or when they require invasive procedures. In addition, the actual therapeutic goal is the final clinical outcome, which is, therefore, usually taken as the endpoint of pharmacogenetic studies. One limitation, however, is that clinical outcomes are often the result of complex and overlapping variables, which may have different genetic and non-genetic causes. As a consequence, the strict genotype-phenotype correlation may be compromised, and the results of pharmacogenetic studies may be difficult to interpret. This is exactly the scenario of breast cancer treatment: although there are theoretical bases and practical evidences that genetic influences may indeed affect the pharmacological response, there is great uncertainty about the usefulness of the genetic information to actually predict clinical outcomes and even more on the confidence of using such individual genetic information to modify one's therapeutic conduct.

The first therapeutic target to drive the attention of pharmacogenetic studies to breast cancer therapy was CYP2D6 in view of its apparent strong genotype-phenotype correlation. Thus, various literature reports indicated that genetic variations in *CYP2D6* affect the availability or the functional activity of the corresponding enzyme (Jin et al., [@B42]), and that such variations in the enzymatic activity ultimately lead to altered levels of tamoxifen metabolites (Lim et al., [@B49], [@B50]; Kiyotani et al., [@B46]; de Graan et al., [@B16]; Irvin et al., [@B37]; Mürdter et al., [@B61]). In addition, parallel observations indicated that altered levels of the most active tamoxifen metabolite, endoxifen, result in reduced binding to the estrogen receptor and to lower signaling transduction (Coezy et al., [@B13]; Lim et al., [@B52]). Taken together, these results have reinforced the notion that *CYP2D6* polymorphisms could be useful to predict one individual's response to tamoxifen, and that *CYP2D6* genotyping might help the selection of the antiestrogenic drug or the definition of tamoxifen dosing. The promises of this rationale in relation to possible improvements in breast cancer outcomes has led to the expansion of pharmacogenomic studies to other therapeutic targets in breast cancer antineoplastic chemotherapy, as well as to other targets of tamoxifen pharmacokinetics.

The evaluation of the literature production involving the pharmacogenetics of breast cancer indicates a great number of studies. The current review, which was focused on pharmacokinetic targets, and more specifically, on functional polymorphisms of xenobiotic metabolizing enzymes, has initially retrieved 158 references on the subject. Although the criteria for the systematic search included the mention to xenobiotic metabolizing enzymes in the article's title or abstract, most of the retrieved documents explored different targets as their main research subject. The most frequent targets besides xenobiotic metabolizing enzymes that were identified in the current search were drug transporters, which might contribute to antineoplastics' pharmacokinetics, affecting drug distribution and disposition, and aromatases, which modulate the availability of estrogens, and the estrogen receptor. The selection of documents exploring functional polymorphisms of xenobiotic metabolizing enzymes resulted in 43 original articles, 23 devoted to tamoxifen, and 20 dealing with various antineoplastic protocols. Among the articles involving tamoxifen, *CYP2D6* was the main pharmacogenetic target, whereas multiple xenobiotic metabolizing enzymes were explored with regards to different cytotoxic antineoplastics. This conjunct of original articles on the pharmacogenetics of breast cancer is still relatively limited in number and very diverse in design. Consequently, general conclusions are difficult to extract at this point, and no clear recommendations can be made for application in clinical practice. Nevertheless, the use of the same terms for bibliographic search without the restriction to original articles indicates that 24 reviews were published on the subject in the same period of time. Although the analysis of the reviews was not part of our systematic search, an overview of the publications indicates that *CYP2D6* predominates as the chosen subject, probably as a reflex of the great enthusiasm after the earliest studies. Some of the most recent reviews already include data on other xenobiotic metabolizing enzymes, but no systematic review had been presented before.

The studies on *CYP2D6* polymorphisms and their influences on tamoxifen efficacy show many discrepancies, which can be accounted to multiple factors, including variations in study design, in the definitions of breast cancer disease, and in the population characteristics. Thus, in relation to study design, different *CYP2D6* polymorphisms are analyzed, and some studies use tumor tissue for genotype assessment, which can compromise the accurate characterization of the number and types of *CYP2D6* alleles. There are also variations in the therapeutic regimen, including adjuvant, neoadjuvant and palliative treatment, and evaluation of different disease outcomes. The prescribed tamoxifen dose may also vary, and, in most studies, there is no control or documentation of drug adherence and of concomitant use of CYP2D6 inhibitors. The population characteristics also present great variability, including different ethnic and cultural backgrounds, which can interfere with risk estimates. Finally, the percentage of postmenopausal women may also be an interfering factor, if there is no control of the use of aromatase inhibitors after the completion of tamoxifen treatment.

A meta-analysis published by Seruga and Amir ([@B85]) analyzed data from 10 studies assessing CYP2D6 genotype and clinical outcomes in breast cancer. The authors found significant heterogeneity in the definition of comparison groups between studies, but suggested that normal CYP2D6 function was associated with a trend toward improved disease-free survival (HR 2.07, 95% CI 0.96--4.49, *P* = 0.06). The most recent work on the subject, by Regan et al. ([@B77]), enrolled a large number of postmenopausal patients treated with tamoxifen for 5 years, as part of the BIG 1--98 trial, and showed no association between CYP2D6 metabolizing phenotype and the risk of recurrence (characterized by the breast cancer-free interval), with or without previous chemotherapy. The patients who were identified as poor or intermediate metabolizers (based on alleles \*2, \*3, \*4, \*6, \*10, \*17, and \*41) did not have worse disease outcomes than extensive metabolizers, or higher chance of presenting hot flushes as side effects. The authors argued that CYP2D6 metabolizing phenotype is not the correct surrogate for predicting symptoms or outcome of tamoxifen-treated postmenopausal women, and advocated that *CYP2D6* pharmacogenetic testing to determine whether adjuvant tamoxifen should be given to postmenopausal women with endocrine-responsive breast cancer is not justified (Regan et al., [@B77]). Although very large in the number of patients enrolled, and with a well-planned prospective design, one limitation of the work by Regan et al. ([@B77]), as acknowledged by the authors, is the use of tumor samples for genotyping, which could lead to some misclassification of metabolizing phenotypes. In addition, the trial did not provide data on concomitant medications, and therefore, a possible interference of CYP2D6 inhibitors cannot be ruled out.

Two other large studies involving breast cancer survivors who used tamoxifen (Abraham et al., [@B1]; Madlensky et al., [@B54]) also suggested the lack of association between *CYP2D6* genotypes, or estimated CYP2D6 metabolizing phenotypes, and breast cancer outcomes. Thus, Abraham et al. ([@B1]) found that only the allele \*6 was associated with lower breast cancer-specific survival, whereas the other alleles (\*4, \*5, \*9, \*10, and \*41) had no significant effects. Madlensky et al. ([@B54]) found no significant associations between CYP2D6 metabolizing phenotypes and the risk of breast cancer recurrence or second breast cancer. The latter authors, however, reported that patients with endoxifen concentrations lower than 5.97 ng/mL were at higher risk of breast cancer recurrence, and that the proportion of decreased CYP2D6 metabolizing phenotype was higher in this group. In addition to CYP2D6 metabolizing phenotype, the authors identified other variables, such as excess weight and low tamoxifen levels (suggesting failures in adherence), which were associated with low endoxifen levels, but not independently associated with breast cancer outcomes. The authors suggested the existence of a non-linear dose-response effect for tamoxifen, and proposed that a threshold of endoxifen must be achieved for the therapeutic effect of tamoxifen. Finally, the authors argued that the metabolizing phenotype alone is not enough to determine whether tamoxifen is of potential benefit to any individual patient (Madlensky et al., [@B54]).

Another aspect with pharmacogenetic interest in relation to tamoxifen is the occurrence of side effects, especially hot flushes, which are intrinsically correlated with the suppression of estrogen signaling, and thus expected to be associated with endoxifen levels. Some authors have proposed that hot flushes could serve as surrogates of tamoxifen efficacy, and that their absence could indicate patients at higher risk of recurrence (Cuzick et al., [@B14]; Mortimer et al., [@B59]). As a logical consequence, it has been hypothesized that poor CYP2D6 metabolizers would be less likely to experience moderate to severe hot flushes (Goetz et al., [@B28]; Henry et al., [@B32]), whereas, in contrast, extensive metabolizers would be more prone to prematurely discontinue tamoxifen, possibly as a consequence of severe hot flushes (Rae et al., [@B76]). The assumed correlation between CYP2D6 metabolizing phenotypes and hot flushes, however, was based on few and weak associations, with no (or only border-line) statistical significance, which were not validated in the recent large prospective study by Regan et al. ([@B77]). Unfortunately, there have been no similar large observational studies evaluating CYP2D6 metabolizing phenotypes and hot flushes as possible causes of non-adherence or non-persistency to tamoxifen treatment. It would be also interesting to have studies evaluating the correlation between endoxifen levels and the occurrence of severe hot flushes.

The metabolism of tamoxifen involves other metabolizing enzymes than CYP2D6, such as CYP3A4/5, 2C8/9, SULT1A1, UGT1A8, UGT2B7, and UGT2B15, which might also have an impact on the availability of endoxifen and other metabolites, and therefore contribute for the heterogeneity in breast cancer outcomes. However, there are few studies evaluating genetic polymorphisms on such metabolic activities and their consequences on tamoxifen efficacy. In addition, the assumption that tamoxifen efficacy is mainly dependent on the availability of endoxifen must also be considered with a certain caution. Although endoxifen has greater affinity for the estrogen receptor than tamoxifen or *N*-desmethyl-tamoxifen (Coezy et al., [@B13]; Jordan, [@B44]; Robertson et al., [@B79]), and higher plasma concentrations than 4-hydroxy-tamoxifen (Johnson et al., [@B43]; Lim et al., [@B51]), it has been estimated that tamoxifen and its metabolites other than endoxifen are capable of nearly saturating estrogen receptors, with 99.94% occupancy (Dowsett and Haynes, [@B20]). Therefore, impaired tamoxifen metabolism may not represent a full limitation for tamoxifen efficacy, other cellular mechanisms must be considered when evaluating tamoxifen resistance. Thus, Kim et al. ([@B45]) have shown that tumor cells with low mRNA expression of the estrogen receptor (*ESR1*) present increased tamoxifen resistance when compared to cells with high-level mRNA expression, regardless of endoxifen concentrations. Finally, recent studies have suggested that tamoxifen and its metabolites may have secondary pharmacological actions, such as blockade of voltage-dependent Ca^2+^ channels (Kuo et al., [@B47]), vasodilation (Montenegro et al., [@B58]), and aromatase inhibition (Lu et al., [@B53]). The possible impact of such additional pharmacological mechanisms on breast cancer is not known yet.

The evaluation of studies involving chemotherapeutic protocols for breast cancer therapy indicates that many xenobiotic metabolizing enzymes other than CYP2D6 are also being considered as possible pharmacogenetic targets. These studies indicate great diversity of antineoplastic protocols and a balanced interest in both efficacy and toxicity. The number of studies, however, is still very limited, with only one or very few studies for each pharmacogenetic target, and no confirmation of positive associations. The only exception appears to involve *GSTP1 Ile105Val*, since three different studies (Zárate et al., [@B101]; Yao et al., [@B100]; Zhang et al., [@B102]), exploring anthracycline-based protocols, suggest higher risk of severe hematological toxicity (neutropenia or leucopenia) for patients with variant genotypes. Although there are some inconsistencies regarding the heterozygous genotype, the combined results appear to indicate that the presence of valine instead of isoleucine, which results in decreased enzymatic activity (Watson et al., [@B95]), would favor higher plasma concentrations of the chemotherapeutic drugs, with consequent increased toxicity. Such increased toxicity, as an apparent consequence of increased plasma concentrations, does not seem to have a direct correlation with better response profile. Thus, although Zhang et al. ([@B102]) have reported better pathological response for patients with the *G/G (Val/Val)* genotype after neoadjuvant therapy, Huang et al. ([@B35]) found that patients with variant genotypes had higher rates of early relapse after adjuvant treatment, and other authors found no significant effects of the *GSTP1 Ile105Val* polymorphism on the therapeutic response after adjuvant (Gor et al., [@B29]; Yao et al., [@B100]) or neoadjuvant treatment (Oliveira et al., [@B68]).

The above results point an important aspect of pharmacogenetic studies in clinical oncology, which is the apparent higher variability in the results involving response outcomes than in those related to drugs' toxicities. This is not surprising considering that, in addition to the subjects' polymorphisms, tumors might also present mutations, as well as epigenetic variations that could affect cellular response to chemotherapy. Secondly, an individual clinical response also involves many non-genetic factors that are difficult to control, such as lifestyle, comorbidities, drug interactions, and treatment adherence. Finally, in the case of breast cancer, clinical outcomes have a long time frame, which make them more difficult to study in a controlled design. Although it is logical that prospective observational studies combining the evaluation of pharmacogenetic data and non-genetic patients' characteristics would be ideal for modeling breast cancer clinical outcomes, their practical implementation is certainly a challenge.

Another important issue raised by the example of the results involving *GSTP1 Ile105Val* involves the translation of pharmacogenetic data into the clinical practice of oncology. Let's assume that a genotype-phenotype is established, and that it involves a pharmacokinetic target, with an apparent plasma concentration-dependent relationship. In such scenario, should one individual's dose be adjusted based on the identified genotype? For example, should patients with the homozygous variant *GSTP1* genotype receive lower doses as an attempt to reduce their risk of severe neutropenia, and therefore avoid treatment delays or interruption that could compromise the final response outcomes? Although the genotype-phenotype relationship might be recognized when evaluating the risk estimates in a population, there is no absolute correspondence between genotypes and outcomes at the individual level. In addition, there is certainly great concern about reducing the dose, and consequently increasing the risk of lower response. Thus, it seems unlikely that such prophylactic dose adjustments based on an individual genotype would even be tested in a clinical trial, and ultimately incorporated for oncological treatments. Alternatively, should patients at estimated higher risk of toxicity receive some prophylactic or supportive treatment? For example, in the case of patients with the variant *GSTP1* genotype, should stimulating factors be considered as a strategy to minimize their risk of neutropenia? There is no doubt that the idea of being able to choose a drug guided by an individual genotype, as it was initially considered for tamoxifen vs. aromatase inhibitors, is more appealing as a practical pharmacogenetic conduct in oncology than the hard and risky task of defining one individual's antineoplastic dose. Nevertheless, the current recommendations of the American Society of Clinical Oncology (ASCO) do not include routine *CYP2D6* testing to select the endocrine therapy (Burstein et al., [@B10]).

Conclusion and Perspectives
===========================

The application of pharmacogenetics to predict breast cancer therapeutic outcomes and to select one individual's chemotherapeutic protocol is still far from clinical routine. Most studies used the candidate-gene approach, and evaluated single or few SNPs in metabolic pathways. In addition, because of the difficulties of conducting large trials, most studies explored the most common genetic variations. Although some very interesting results have been produced, no clear practical recommendations are recognized yet. The current challenge is to simultaneously evaluate multiple genes and pathways, including rarer variants, and to consider their combined effects on drug efficacy and toxicity. Such endeavor will require large, multicentric studies, and longer and well-controlled follow-ups, in order to produce reliable information, aiming at consequent practical applications for breast cancer therapy.

These above conclusions regarding the constraints for clinical applicability of pharmacogenomic data in breast cancer management meet the consensus view on the use of qualifying biomarkers in drug safety (Agúndez et al., [@B2]). It appears, thus, that the limitations of pharmacogenomic studies are not a particularity of Oncology, and that the use of genetic information as biomarkers requires medical and scientific consensus and the development of adequate guidelines for clinical practice. Research consortia appear to be good opportunities to explore these goals.
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